X
Oct 18, 2021 04:44 PM (GMT+8) · EqualOcean
Financial Associated Press, October 18 - Sansheng Guojian announced that the company's "an open, multicenter, phase I / II study to evaluate the safety, tolerance, pharmacokinetics and preliminary efficacy of ssgj-706 in subjects with advanced solid tumor, recurrent or refractory lymphoma" was approved by the U.S. Food and Drug Administration (FDA) to enter the phase I / II clinical study. Ssgj-706 is a recombinant bispecific antibody developed by Sansheng Guojian with independent intellectual property rights (bispecific antibody platform).

This text is a result of machine translation.